EcoDrugPlus

Proteasome Subunit Beta Type-3-Like

Ensembl ID : ENSOTSG00005027339
Gene Symbol: LOC112264476
3 Cross references
253 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSOTSG00005030479
Gene Symbol: LOC112248926
3 Cross references
158 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSOTSG00005039304
Gene Symbol: LOC112251100
3 Cross references
158 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSOTSG00005045561
Gene Symbol: LOC112229789
3 Cross references
164 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSOTSG00005045431
Gene Symbol: LOC112233302
3 Cross references
212 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSOTSG00005023197
Gene Symbol: LOC112233302
3 Cross references
212 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSOTSG00005047912
Gene Symbol: PRMT5
1 Cross references
192 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSOTSG00005040916
Gene Symbol: PRMT5
1 Cross references
192 Possible Orthologues:

Protein Farnesyltransferase/geranylgeranyltransferase Type-1 Subunit Alpha-Like

Ensembl ID : ENSOTSG00005046234
Gene Symbol: LOC112256360
3 Cross references
215 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSOTSG00005005661
Gene Symbol: PRKCA
3 Cross references
207 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSOTSG00005012264
Gene Symbol: PRKCD
3 Cross references
196 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSOTSG00005038959
Gene Symbol: PRKCD
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).